Karen Aiach, CEO of Lysogene, to Deliver Keynote, “Rare Informs the Common” at “Precision Medicine 2016: Rogue Therapeutics” Conference

Karen Aiach, CEO of Lysogene, to Deliver Keynote, “Rare Informs the Common” at “Precision Medicine 2016: Rogue Therapeutics” Conference 150 150 Lysogene

Wednesday, June 8

Lysogene today announced that Karen Aiach, the company’s Founder and Chief Executive Officer, will be the keynote speaker at “Precision Medicine 2016: Rogue Therapeutics”. The conference, hosted by the Department of Biomedical Informatics at Harvard Medical School, will take place on June 22, 2016 in Boston, MA.

“I am grateful and delighted to be the keynote speaker at this year’s prestigious conference, and I look forward to sharing our clinical journey at Lysogene and commitment to continuously advancing the development of gene therapies for patients with neurodegenerative diseases,” said Karen Aiach. “Today, I am proud to say that our company has made accelerating progress with our programs in Sanfilippo Syndrome (MPS IIIA ) and GM1 Gangliosidosis.”

“We all can learn from the brave leadership of Karen Aiach,” said Isaac (Zak) Kohane, Chairman of the Department of Biomedical Informatics (DBMI) at Harvard Medical School. “We are entering an era where real patient engagement will drive therapeutic innovation.”

“Precision Medicine 2016: Rogue Therapeutics” will highlight and feature individuals who are blazing new paths to find therapeutics that target rare and at times misdiagnosed diseases.  Topics covered at the conference include, “What is driving Precision Medicine?”, “What happens when patients take over?”, “Will engineering disrupt therapeutics?”, and “Marijuana: recreational to medicinal?”.

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top